Member Info for EmeraldCarrots

No better things to do?

System (Dynamic Purchasing System) !!!!!!!!!!!!!!!

https://www.supplychain.nhs.uk/programmes/product-innovation-for-customers/strategy-opportunities-for-medical-technology-products/

NHS finally taking on board testing babies to make sure they won't go deaf after receiving antibiotics is a tad important to parents, doctors and nurses!!!

Thanks Lionel1 for your post!!!!!!!!!!!

Kit test. Elderly people (or anyone) might pay a small fee to find out if they are resistant to the blood thinner used in NHS after stroke care (CYP2C19-ID Kit). If they had a stroke knowing this in advance might save their life. It would get good publicity for Boots and Genedrive. Maybe it could be offered at the biggest Boots chemists?

Pharmacies .". You mean like Boots?

Financial issues?

The MT-RNR1 machine all ready has it. Expectyed for the Genedrive® CYP2C19 THIS MONTH.

EU Member States:

Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden.

EEA Countries:

Iceland, Liechtenstein, and Norway.

Other Countries:

While not part of the EU or EEA, Turkey and Switzerland also require CE marking for certain products.

CE Marking:

The CE marking is a mandatory certification mark for products sold within the European Economic Area (EEA) and indicates that a product meets certain health, safety, and environmental protection requirements. According to GOV.UK, the CE marking must be placed on the product by the manufacturer, or by their authorized representative within the EEA or Turkey, where permitted.

"Market access routes and reimbursement strategies defined in key initial international target countries, including the Middle East region, with well-positioned and aligned in-country distributors, with required regulatory certification (CE-IVD under IVDR) on track for ***April 2025.2***. Not long now!

Genedrive® CYP2C19

· First UK commercial sales of the Genedrive® CYP2C19-ID Kit to England's largest Hyperacute Stroke Centre

· North West Anglia Foundation NHS Trusts' Peterborough City Hospital implements the Genedrive® CYP2C19-ID Kit for routine clinical use

· Growing base of initial installations for site verifications expected to lead to subsequent routine clinical use

· Positive value assessment by the Scottish Health Technologies Group (SHTG) following referral by the Accelerated National Adoption (ANIA) pathway group in Scotland, leading to the Scottish Government announcement of investment to support national pharmacogenetic testing of CYP2C19 in Stroke patients, including genedrive's CYP2C19-ID test for rapid genetic testing in Transient Ischaemic Attack (TIA) patients

· NICE recommendation of the Genedrive® CYP2C19-ID Kit as the rapid genetic testing platform of choice for CYP2C19 genotyping strategies for clopidogrel administration in ischaemic stroke (IS) and TIA, with Genedrive's CYP2C19 ID Kit being dominant in cost effectiveness models

· Genedrive® CYP2C19-ID Kit clinical performance published in Journal of Molecular Diagnostics (December 2024), outlining superior performance to laboratory test and alternative available point of care (PoC) platforms with respect to target coverage, speed, accuracy and test fails

· Inclusion in study aimed at understanding how best to deliver CYP2C19 based genotyping at scale throughout the NHS, and accepted on NHS Dynamic Procurement System (DPS), permitting direct procurement by regional NHS trusts

· Market access routes and reimbursement strategies defined in key initial international target countries, including the Middle East region, with well-positioned and aligned in-country distributors, with required regulatory certification (CE-IVD under IVDR) on track for April 2025

· 510(k) route identified for regulatory submission for US market entry, with initial pre-submission engagement with Food and Drug Administration (FDA) held and feedback positive and with regulatory approach confirmed as appropriate

Go up. I assume you realised that a long time ago. So either has a short position, wants a lower price to buy in or upset investor from the past.

Up 2.52%.

for new born babies. This machine is unique to the USA as confirmed by the FDA ! Needed in every neonatal ward in the ENTIRE WORLD. Sales will SNOWBALL !!!!!!!!!!!!!!!!!

Ask now over the placing price.

1.49/1.52p

Dow futures up 1,100 points.

All IMHO!

Genedrive don't sell to the USA FFS! Also even if we do in 6 months after FDA approval etc.. we could move production to the USA if necessary, although we only have the 10% tarrif anyway. What a load of utter rubbish on here. Shorters panicing - dow futures up 1,200 points.................... Children posting again on here I think.

USA market opens @ uk time 2:30pm.

Dow futures up over 1,000.

Up 3.03%.

We are off. Back to 10p?

To prevent babies suffering total hearing loss from an adverse reaction to antibiotic. Parents, doctors and nurses need this vital machine to test babies. Sales will surely take off!!!!!!

All IMHO.

And Illumina etc...........

https://web.hansonwadegroup.com/rs/355-DOS-429/images/15th-Clinical-Biomarkers-Companion-Diagnostics-Summit-Europe-Full-Event-Guide.pdf

With the rest of the market, should recover.

In new born babies. This machine is unique to the USA as confirmed by the FDA ! Needed in every neonatal ward in the ENTIRE WORLD. Sales will SNOWBALL !!!!!!!!!!!!!!!!!

And Illumina etc...........

https://web.hansonwadegroup.com/rs/355-DOS-429/images/15th-Clinical-Biomarkers-Companion-Diagnostics-Summit-Europe-Full-Event-Guide.pdf

Europe. Angle presenting plus Astrazeneca and Illumina etc...........

https://web.hansonwadegroup.com/rs/355-DOS-429/images/15th-Clinical-Biomarkers-Companion-Diagnostics-Summit-Europe-Full-Event-Guide.pdf

NHS trusts to use their own budgets to buy the MT-RNR1 for neonatal wards. Not available for use = possibly a newborn will have a bad reaction to antibiotic and go deaf!!!!!!! Massive pressure, must be. Market bounce tomorrow pencilled in, money has been moved in the last few days out generally, now it will be targeting the Co's that should not have been sold off........ i.e WIZZ air and CCL (Carnival Cruises). CCL have very recently posted RECORD bookings for ......... NEXT year and they got hammered too. Crazy or what!! Up over the pond I see....... Also oil right down. About 20% of airlines running cost is fuel, and some cruise ships cost $250,000 to re-fuel. Nuff said?

All IMHO.